Lexeo Therapeutics, Inc. (LXEO) Financial Statements
Free cash flow over the same period: -$88.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LXEOLexeo Therapeutics, Inc.Follow LXEO — free
—
Price chart with a free account
- Market cap
- 229.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Research & development | 53.1 | 74.1 | 63.8 | 66.6 | |
| Operating income | -68.5 | -105.8 | -109.3 | -95.1 | |
| Pre-tax income | -66.4 | -98.4 | -99.7 | -87.0 | |
| Income tax | — | 0.0 | 0.0 | — | |
| Net income | -66.4 | -98.3 | -100.0 | -87.3 | |
| Diluted EPS ($) | -12.40 | -3.09 | -1.86 | -1.01 | |
| Diluted shares (mn) | 5.4 | 31.8 | 53.6 | — |
USD millions · SEC XBRL
Lexeo Therapeutics, Inc. — questions
- What is Lexeo Therapeutics, Inc.'s net income?
- -$87.3M over the twelve months to 2026-06-30.
- What is Lexeo Therapeutics, Inc.'s free cash flow?
- -$88.7M over the twelve months to 2026-06-30.
- What are Lexeo Therapeutics, Inc.'s diluted earnings per share?
- $-1.01 over the twelve months to 2026-06-30.
Every figure on this page comes from Lexeo Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.